By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting originating in Munich, Germany, by NewsRx journalists, research stated, "Adoptive immunotherapy is a promising therapeutic approach for the treatment of chronic infections and cancer. T cells within a certain range of high avidity for their cognate ligand are believed to be most effective."
The news reporters obtained a quote from the research from Technical University, "T cell receptor (TCR) transfer experiments indicate that a major part of avidity is hardwired within the structure of the TCR. Unfortunately, rapid measurement of structural avidity of TCRs is difficult on living T cells. We developed a technology where dissociation (koff rate) of truly monomeric peptide-major histocompatibility complex (pMHC) molecules bound to surface-expressed TCRs can be monitored by real-time microscopy in a highly reliable manner. A first evaluation of this method on distinct human cytomegalovirus (CMV)-specific T cell populations revealed unexpected differences in the koff rates. CMV-specific T cells are currently being evaluated in clinical trials for efficacy in adoptive immunotherapy; therefore, determination of koff rates could guide selection of the most effective donor cells. Indeed, in two different murine infection models, we demonstrate that T cell populations with lower koff rates confer significantly better protection than populations with fast koff rates."
According to the news reporters, the research concluded: "These data indicate that koff rate measurements can improve the predictability of adoptive immunotherapy and provide diagnostic information on the in vivo quality of T cells."
For more information on this research see: TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Science Translational Medicine, 2013;5(192):192ra87 (see also technology.html">Biotechnology).
Our news correspondents report that additional information may be obtained by contacting M. Nauerth, Institute for Medical Microbiology, Immunology and Hygiene, Technische Universitat Munchen, 81675 Munich, Germany. Additional authors for this research include B. Weißbrich, R. Knall, T. Franz, G. Dossinger, J. Bet, P.J. Paszkiewicz, L. Pfeifer, M. Bunse, W. Uckert, R. Holtappels, D. Gillert-Marien, M. Neuenhahn, A. Krackhardt, M.J. Reddehase, S.R. Riddell and D.H Busch.
Keywords for this news article include: Biotechnology, Munich, Europe, Germany, Therapeutics, Immunotherapy, Immunomodulation, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC